APA (7th ed.) Citation

N, P., R, M., C, G., S, B., L, M., Y, S., . . . J, B. (2026). STAT2 R148 variant: A 16th-century founder mutation and clinical response to high-dose JAK inhibitor therapy. Journal of human immunity, 2(4), e20260001. https://doi.org/10.70962/jhi.20260001

Chicago Style (17th ed.) Citation

N, Parvaneh, et al. "STAT2 R148 Variant: A 16th-century Founder Mutation and Clinical Response to High-dose JAK Inhibitor Therapy." Journal of Human Immunity 2, no. 4 (2026): e20260001. https://doi.org/10.70962/jhi.20260001.

MLA (9th ed.) Citation

N, Parvaneh, et al. "STAT2 R148 Variant: A 16th-century Founder Mutation and Clinical Response to High-dose JAK Inhibitor Therapy." Journal of Human Immunity, vol. 2, no. 4, 2026, p. e20260001, https://doi.org/10.70962/jhi.20260001.